Feed RPRX
RP

Royalty Pharma

RPRX · NASDAQ

$57.65 -1.49% (-$0.87)
1M -4.71%
Market Cap $25.9B
P/E Ratio 31.80x
Div. Yield 1.58%
ROE 12.25%

Bulios Fair Price

$43.23

25.0% downside

Current Price

$57.65

Undervalued Fair Value Overvalued

According to Bulios Fair Price, RPRX is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
46 /100
Fair
EV/EBITDA 19.86x
P/S 10.22x
P/B 3.79x
Growth
57 /100
Stable
Rev. growth 2.06%
FCF growth 5.11%
Book val. growth 4.79%
Profitability
100 /100
Strong
Net margin 32.15%
Op. margin 62.34%
FCF margin 117.37%
Quality
43 /100
Average
ROE 12.25%
ROA 4.11%
Asset turnover 0.13x
Debt
36 /100
Moderate
Current ratio 1.29x
Int. coverage 4.74x
Net debt/EBITDA 4.75x
Stability
59 /100
Moderate
Rev. volatility 5.21%
EPS volatility 1,411.73%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RPRX
Online

About the company

Royalty Pharma plc is an international pharmaceutical company based in New York, USA, specializing in investments in royalty and licensing rights to pharmaceutical products. The company focuses on providing financial resources to research and development pharmaceutical companies in exchange for rights to profits from the sale of their drugs.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Pablo Legorreta

Employees

100

Headquarters

New York

Upcoming events

04 NOV

Earnings

Upcoming earnings report

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.